CLINICAL USE

Control of extrapyramidal symptoms Acute dystonias

DOSE IN NORMAL RENAL FUNCTION

Oral: 2.5–10 mg 3 times a day; maximum 60 mg dailyAcute dystonias: IM/IV: 5–10 mg

PHARMACOKINETICS

  • Molecular weight                           :323.9
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : <5
  • Volume of distribution (L/kg)       :1
  • half-life – normal/ESRD (hrs)      :12/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    IV, IM, oral

    Rate of Administration

    Bolus over 3–5 minutes

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia